SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations
<i>Background</i>: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used in patients with type 2 diabetes, chronic kidney disease, and heart failure. However, their safety and efficacy in patients with congenital or surgically altered urogenital anatomy remains underex...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/5/921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850126207633326080 |
|---|---|
| author | Mohammed Abdulrasak Ali Someili Mostafa Mohrag |
| author_facet | Mohammed Abdulrasak Ali Someili Mostafa Mohrag |
| author_sort | Mohammed Abdulrasak |
| collection | DOAJ |
| description | <i>Background</i>: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used in patients with type 2 diabetes, chronic kidney disease, and heart failure. However, their safety and efficacy in patients with congenital or surgically altered urogenital anatomy remains underexplored. <i>Methods</i>: We conducted a narrative review of current evidence regarding the use of SGLT2i in patients with urinary tract malformations, urinary diversions, and functional voiding disorders. Key risks, clinical considerations, and management strategies were synthesized from the existing literature and case reports. <i>Results</i>: Patients with benign prostatic hyperplasia, vesicoureteral reflux, neurogenic bladder, nephrostomies, and ileal conduits may face increased risks of urinary tract infections, fungal colonization, and therapy-related complications due to persistent glycosuria and altered urinary flow. Nevertheless, these patients may still benefit from SGLT2i’s systemic renal and cardiovascular effects. Individualized risk assessment, close monitoring, and multidisciplinary management are essential. <i>Conclusions</i>: Patients with urological abnormalities represent a high-risk but potentially high-reward population for SGLT2i therapy. A cautious, tailored approach is necessary, and future dedicated research is urgently needed to better guide clinical practice. |
| format | Article |
| id | doaj-art-486335073daf4cb69f124c763ae544fd |
| institution | OA Journals |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-486335073daf4cb69f124c763ae544fd2025-08-20T02:33:58ZengMDPI AGMedicina1010-660X1648-91442025-05-0161592110.3390/medicina61050921SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical ConsiderationsMohammed Abdulrasak0Ali Someili1Mostafa Mohrag2Department of Clinical Sciences, Lund University, 22100 Malmo, SwedenDepartment of Medicine, Faculty of Medicine, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Medicine, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia<i>Background</i>: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used in patients with type 2 diabetes, chronic kidney disease, and heart failure. However, their safety and efficacy in patients with congenital or surgically altered urogenital anatomy remains underexplored. <i>Methods</i>: We conducted a narrative review of current evidence regarding the use of SGLT2i in patients with urinary tract malformations, urinary diversions, and functional voiding disorders. Key risks, clinical considerations, and management strategies were synthesized from the existing literature and case reports. <i>Results</i>: Patients with benign prostatic hyperplasia, vesicoureteral reflux, neurogenic bladder, nephrostomies, and ileal conduits may face increased risks of urinary tract infections, fungal colonization, and therapy-related complications due to persistent glycosuria and altered urinary flow. Nevertheless, these patients may still benefit from SGLT2i’s systemic renal and cardiovascular effects. Individualized risk assessment, close monitoring, and multidisciplinary management are essential. <i>Conclusions</i>: Patients with urological abnormalities represent a high-risk but potentially high-reward population for SGLT2i therapy. A cautious, tailored approach is necessary, and future dedicated research is urgently needed to better guide clinical practice.https://www.mdpi.com/1648-9144/61/5/921SGLT2 inhibitorsurogenital malformationsurinary tract infectionsurinary diversionsbenign prostatic hyperplasia |
| spellingShingle | Mohammed Abdulrasak Ali Someili Mostafa Mohrag SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations Medicina SGLT2 inhibitors urogenital malformations urinary tract infections urinary diversions benign prostatic hyperplasia |
| title | SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations |
| title_full | SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations |
| title_fullStr | SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations |
| title_full_unstemmed | SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations |
| title_short | SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations |
| title_sort | sglt2 inhibitors in patients with urogenital malformations and urinary diversions risks benefits and clinical considerations |
| topic | SGLT2 inhibitors urogenital malformations urinary tract infections urinary diversions benign prostatic hyperplasia |
| url | https://www.mdpi.com/1648-9144/61/5/921 |
| work_keys_str_mv | AT mohammedabdulrasak sglt2inhibitorsinpatientswithurogenitalmalformationsandurinarydiversionsrisksbenefitsandclinicalconsiderations AT alisomeili sglt2inhibitorsinpatientswithurogenitalmalformationsandurinarydiversionsrisksbenefitsandclinicalconsiderations AT mostafamohrag sglt2inhibitorsinpatientswithurogenitalmalformationsandurinarydiversionsrisksbenefitsandclinicalconsiderations |